ash 2010 intro

October 29, 2010

Dear Colleague: In recent years, experts in the field of hematologic malignancies have seen a panoply of drugs gain a place in our treatment armamentarium. Some of the breakthroughs include the approval of histone deacetylase (HDAC) inhibitors in chronic lymphocytic leukemia (CLL) and peripheral lymphoma; the application of novel alkylating agents, such as bendamustine (Treanda), in CLL and various lymphomas; and the incorporation of dasatinib (Sprycel) for treating chronic myeloid leukemia patients who prove resistant to imatinib (Gleevec). We now find ourselves focusing on how to design the most effective strategies, including drug sequencing, to maximize benefit for our patients. The 2010 American Society of Hematology meeting (ASH) offers the chance to delve deeper into the best ways to maximize treatment for our patients. Join Oncology NEWS International for onsite reports from ASH 2010 as we bring you a bird’s eye view of the research, trials, scientific advances, and controversies that are changing the way hematologic malignancies are managed and treated. Check back here daily during the meeting and watch your inbox for our exciting reports from the ASH 2010 meeting.

American Society of Hematology

 

Dear Colleague:

In recent years, experts in the field of hematologic malignancies have seen a panoply of drugs gain a place in our treatment armamentarium. Some of the breakthroughs include the approval of histone deacetylase (HDAC) inhibitors in chronic lymphocytic leukemia (CLL) and peripheral lymphoma; the application of novel alkylating agents, such as bendamustine (Treanda), in CLL and various lymphomas; and the incorporation of dasatinib (Sprycel) for treating chronic myeloid leukemia patients who prove resistant to imatinib (Gleevec).

We now find ourselves focusing on how to design the most effective strategies, including drug sequencing, to maximize benefit for our patients. The 2010 American Society of Hematology meeting (ASH) offers the chance to delve deeper into the best ways to maximize treatment for our patients. Join Oncology NEWS International for onsite reports from ASH 2010 as we bring you a bird’s eye view of the research, trials, scientific advances, and controversies that are changing the way hematologic malignancies are managed and treated.

Check back here daily during the meeting and watch your inbox for our exciting reports from the ASH 2010 meeting.